Beam therapeutics inc. (BEAM) 2025Q4 financial report shows that the ROE at 19.73%, ROA at 16.49%, and ROIC at -1.25%. The overall trend of these three indicators directly reflects the company’s capital efficiency and growth momentum. If all three ratios keep rising over recent quarters, it means the company is improving in profitability, asset utilization, and capital returns—showing solid fundamentals and ongoing growth potential. On the other hand, if these ratios are declining, pay attention to whether the company’s strategy is facing challenges or if the industry environment is putting on pressure. For a more complete picture of the company’s operations, it’s recommended to also track revenue growth, operating margin, and other key metrics, and refer to Growin AI Value Scores to understand the company’s financial health and growth outlook.